NCT00724776View on ClinicalTrials.gov

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2009

Conditions
Chronic Hepatitis C
Interventions
BIOLOGICAL

Albinterferon alfa 2b

recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0

Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Japan, Tokyo

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00724776 - Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients | Biotech Hunter | Biotech Hunter